India's Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion, including debt. The Indian generic drugmaker will acquire all outstanding shares of Organon for $14 apiece, according to an exchange filing Monday by Sun Pharmaceutical . "Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders,"